Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29757897 | 1.00 | GPR119 (0.60) | GPR119CHEK2CHRNA3CYP4F2CYP4A11 | |
| SCHEMBL7524902 | 0.93 | GPR119 (0.56) | GPR119CHEK2CHRNA3CYP4F2CYP4A11 | |
| SCHEMBL457651 | 0.87 | GPR119 (0.56) | GPR119CHEK2SLC2A1 | |
| SCHEMBL29674744 | 0.86 | GPR119 (0.60) | GPR119CHEK2CYP4F2CYP4A11SLC2A1 | |
| SCHEMBL20758445 | 0.86 | GPR119 (0.60) | GPR119CHEK2CYP4F2CYP4A11SLC2A1 | |
| SCHEMBL384358 | 0.86 | GPR119 (0.60) | GPR119CHEK2CYP4F2CYP4A11SLC2A1 | |
| SCHEMBL3256200 | 0.86 | GPR119 (0.57) | GPR119CHEK2HDAC1 | |
| SCHEMBL30785455 | 0.84 | GPR119 (0.58) | GPR119CHEK2CYP4F2CYP4A11SLC2A1 | |
| SCHEMBL27158533 | 0.84 | GPR119 (0.58) | GPR119CHEK2CYP4F2CYP4A11SLC2A1 | |
| SCHEMBL1092728 | 0.84 | GPR119 (0.66) | GPR119CHRNA3CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363668-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-11-17 | — | — | US | disclosed |
| EP-4017587-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| CN-114269430-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2021032937-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032936-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032936-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032937-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| EP-2858986-B1 | PIPERIDINE DERIVATIVES AS GPR119 AGONISTS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2019-10-30 | — | — | EP | disclosed |
| US-9944600-B2 | Piperidine derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-04-17 | — | — | US | disclosed |
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-18 | — | — | US | disclosed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | GPR119, FFAR2, GPR84 | GPR119 1/4885CHEK2 3121/4885CHRNA3 587/4885 |
| US-20220363668-A1 | ENZYME INHIBITORS | RNASE1, SERPINB1, CMA1 | GPR119 415/4885CHEK2 2679/4885CHRNA3 3858/4885 |
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | GPR119 1/4885CHEK2 4217/4885CHRNA3 228/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | GPR119 1/4885CHEK2 2703/4885CHRNA3 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.